Product News

Share this article:

GlaxoSmithKline agreed to sell US commercial rights for Wellbutrin XL, an antidepressant, to Biovail Corp. for $510 million, according to a Bloomberg report. Wellbutrin's patent expired over two years ago. GSK will retain rights to the drug outside the US.

 

Rockville, MD-based biotech Vanda Pharmaceuticals secured an FDA approval for its first product, a schizophrenia treatment called Fanapt (iloperidone). The drug will be available in pharmacies later this year, according to a company statement.  

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.